Clinical staging is rarely utilized for melanoma due to inaccuracy of the estimation of lesion thickness as well as regional nodal involvement. However, clinical staging may be utilized to stage metastatic melanomas, or when adequate tissue is unavailable for pathologic assessment. Biopsy and pathologic assessment of the entire tumor (not a shave, punch or wedge biopsy) are crucial for accurate staging.
Tumor thickness as defined by the Breslow’s Depth of Invasion is the most important determinant of prognosis for melanomas. Increased tumor thickness is correlated with metastasis and poorer prognosis. Recent findings have shown that the presence of ulceration microscopically is the second most important determinant of prognosis. Clark’s Level of Invasion measures the level of tumor invasion through the layers of the skin, but has recently been shown to affect prognosis only in melanomas that are <1 mm depth.
Breslow’s depth of invasion is an actual measurement of the depth of the lesion, measured vertically in millimeters from the top of the granular layer (or base of superficial ulceration) to the deepest point of tumor involvement. Tumors are classified into four categories based on the depth:
Less than or equal to 0.75 mm (equivalent to Clark’s Level II)
0.76-1.5 mm (equivalent to Clark’s Level III)
1.51-4 mm (equivalent to Clark’s Level IV)
Greater than or equal to 4 mm (equivalent to Clark’s Level V)
Clark’s level of invasion is based on the level of tumor invasion relative to the layers of the skin. Tumors are classified into five levels:
Level I - All tumor cells are confined to the epidermis, above the basement membrane (in situ)
Level II - Tumor invades into the papillary dermis, past basement membrane
Level III - Tumor fills the papillary dermis and extends to the interface between the papillary and reticular dermis
Level IV - Tumor invades the reticular dermis
Level V - Tumor invasion of subcutaneous tissue
| SEER Summary Stage 2000 | Breslow’s Thickness/Depth | Clark’s Level |
| In Situ | In Situ | Level I |
| Localized | Less than or equal to 0.75 mm | Level II |
| 0.76-1.5 mm | Level III | |
| > 1.5 mm | Level IV | |
| Regional by Direct Extension | Through entire dermis | Level V |
| Satellite nodules < 2cm from primary | ||
| Regional Lymph Nodes | See SSS2000 manual for lymph nodes by primary site | |
| Distant | Underlying cartilage, bone, muscle, or metastatic skin lesions | |
Criteria for TNM Clinical Staging: Because thickness is the primary determinant of prognosis, clinical “T” classification is rarely utilized. Excisional biopsy and histopathologic assessment of primary lesion are necessary for proper staging.
Criteria for TNM Pathologic Staging: Pathologic
staging is based on Breslow’s thickness and Clark’s level of invasion.
Evaluation of entire tumor and adjacent normal skin are required for pathologic
staging; wedge, punch and shave biopsies are inadequate. Regional nodes should
be evaluated, and size of lymph node metastasis should be recorded.
| Stage | TNM Classification | Histological/Clinical Features |
| 0 | pTis N0 M0 | Intraepithelial/in situ melanoma |
| I | pT1 N0 M0
|
Melanoma < = 0.75 mm in thickness, Clark’s level II Melanoma > 0.75 –1.5 in thickness, Clark’s level III |
| II | pT3 N0 M0 | Melanoma > 1.5-4 mm in thickness, Clark’s level IV |
| III | pT4 N0 M0 Any pT N1 M0
|
Melanoma >4 mm in thickness, Clark’s level V Metastasis 3cm or less in greatest dimension in any regional lymph node Metastasis more than 3cm in greatest dimension in any regional lymph node and/or in-transit metastasis |
| IV | Any pT Any N M1 | Distant metastasis |
The AJCC 6th edition includes a heavily revised staging system for melanoma of the skin. Modifications include incorporation of information regarding the presence of ulceration and number of lymph nodes involved rather than size, so that prognosis may be more accurately assessed. Clark’s level is included only for primary tumors <1 mm in thickness (stages IA and IB), because it has been shown to be of low prognostic value for thicker melanoma. Micrometastasis to regional lymph nodes is differentiated from macroscopic nodal metastasis.
| Factor | AJCC 5th Edition | AJCC 6th Edition |
| Thickness | Secondary prognostic factor; thresholds of 0.75, 1.5 and 4.0 mm | Primary determinant of T staging; thresholds of 1.0, 2.0 and 4.0 mm |
| Level of invasion | Primary determinant of T staging | Used only for defining T1 melanomas |
| Ulceration | Not included | Included as a second determinant of T and N staging |
| Satellite metastases | In T category | In N category |
| Thicker melanomas (>4.0 mm) | Stage III | Stage IIC |
| Size of nodal metastases | Dominant determinant of N staging | Not used |
| Number of nodal metastases | Not included | Primary determinant of N staging |
| Metastatic tumor burden | Not included | Included as a second determinant of N staging |
| Lung metastases | Merged with all other visceral metastases | Separate category as M1b |
| Elevated serum LDH | Not included | Included as a second determinant of M staging |
| Clinical vs. pathologic staging | Did not account for sentinel node technology | Sentinel node results incorporated into definition of pathologic staging |
(From AJCC 6th Edition staging manual)
Criteria for TNM Clinical Staging: Complete excision of the melanoma, including microstaging, and clinical, radiologic, and laboratory assessment of regional or distant metastasis are required for staging. Microstaging occurs after excisional biopsy with pathologic assessment of Breslow’s thickness, Clark’s level and ulceration.
Criteria for TNM Pathologic Staging: Pathologic staging is based on the same criteria as Clinical Staging, with additional information obtained from pathologic evaluation of regional lymph nodes after sentinel or complete lymphadenectomy, and pathologic confirmation of metastases. Number of lymph node metastases should be recorded, and serum LDH levels should be obtained.
| Stage | TNM Classification | Histological/Clinical Features |
| 0 | Tis N0 M0 | Intraepithelial/in situ melanoma |
| IA | T1a N0 M0 | Melanoma <=1 mm in thickness, Clark’s level II or III, without ulceration |
| IB | T1b N0 M0
|
Melanoma <=1 mm in thickness, Clark’s level IV or V, with ulceration Melanoma 1.01-2 mm in thickness without ulceration |
| IIA | T2b N0 M0
|
Melanoma 1.01-2 mm in thickness with ulceration Melanoma 2.01-4 mm in thickness without ulceration |
| IIB | T3b N0 M0
|
Melanoma 2.01-4 mm in thickness with ulceration Melanoma >4 mm in thickness without ulceration |
| IIC | T4b N0 M0 | Melanoma >4 mm in thickness with ulceration |
| IIIA | T1-4a N1a M0
|
Single regional nodal microscopic metastasis without ulceration of primary lesion 2-3 microscopic positive regional nodes without ulceration of primary lesion |
| IIIB | T1-4bN1a M0
|
Single regional nodal micrometastasis, with ulceration of primary lesion 2-3 microscopic regional nodes, with ulceration of primary lesion Single regional nodal macrometastasis, without ulceration of primary lesion 2-3 macroscopic regional nodes, without ulceration of primary lesion Satellite or in-transit metastasis without metastatic lymph nodes or ulceration of primary lesion |
| IIIC | T1-4b N2a M0
|
Single macroscopic regional node, with ulceration of primary lesion 2-3 macroscopic metastatic regional nodes, with ulceration of primary lesion 4 or more metastatic nodes, matted nodes/gross extracapsular extension, or satellite or in-transit metastasis with metastatic lymph nodes |
| IV | Any T any N M1a
Any T any N M1c |
Metastasis to skin, subcutaneous tissues, or distant lymph nodes Metastasis to lung Metastasis to all other visceral sites or distant metastasis at any site associated with an elevated serum LDH |
Fore more details on Collaborative Stage, see the CS module.